EVTCY - EVTCY STOCK NEWS

Evotec announced a milestone in its neuroscience collaboration with Bristol Myers Squibb, triggering total payments of US$ 40 million due to additional program designations. This achievement reinforces Evotec's pipeline following the licensing of EVT8683. The collaboration, initiated in December 2016, aims to develop disease-modifying treatments for neurodegenerative diseases, addressing significant unmet medical needs. Evotec's advanced iPSC platform supports these initiatives, further establishing its leadership in the field.

Evotec SE has announced a public offering of American Depositary Shares (ADSs) generating gross proceeds of $435 million. The offering involves the sale of 10 million ordinary shares at a price of $21.75 per ADS, representing half an ordinary share. Following the offering, Evotec's share capital will increase to €175,110,695. An additional 3 million ADSs can be purchased by underwriters within 30 days. Trading on the Nasdaq Global Select Market is expected to commence on November 4, 2021.

Evotec SE will release its financial results for the first nine months of 2021 on November 11, 2021. The event includes a conference call at 02:00 pm CET to discuss these results, accessible via various international numbers. A simultaneous slide presentation will be available through a designated link. The company emphasizes its mission in drug discovery and development, aiming to tackle challenging diseases through advanced technology platforms. Forward-looking statements are included with caution on relying on them due to inherent uncertainties.

Evotec SE has initiated a public offering in the U.S. for up to 22 million American Depositary Shares (ADSs), representing 11 million ordinary shares, according to a registration statement filed with the SEC. The offering includes a 30-day option for underwriters to purchase an additional 3.3 million ADSs. Proceeds will be used to expand biologics manufacturing and enhance precision medicine platforms. The final ADS price will be based on the Frankfurt closing price on the pricing date in early November.

Evotec SE has reported its preliminary unaudited financial results for the nine months ending September 30, 2021. Revenues are projected to be between €425 - 435 million, a significant increase from €360.4 million in the same period last year, representing a 24 - 27% like-for-like growth. Adjusted EBITDA is anticipated to be €68 - 72 million, down from €76.9 million in 2020, reflecting planned capacity expansion. Unpartnered R&D expenses are expected to increase by €8 - 11 million. Complete financial results are scheduled for release on November 11, 2021.

Evotec SE has filed a registration statement with the SEC for a proposed offering of shares represented by American Depositary Shares (ADSs) in the U.S. The exact number and price of ADSs are yet to be determined. Evotec aims for a secondary listing on the Nasdaq Global Select Market under the ticker symbol EVO. The offering will be led by BofA Securities and Morgan Stanley as joint book-running managers. The registration statement has not yet become effective, and no sales of these securities can occur until it does.

Evotec SE has expanded its collaboration with Bristol Myers Squibb to include a new cell type, triggering a US$9.0 million payment to Evotec. This collaboration, initiated in December 2016, aims to develop disease-modifying therapies for neurodegenerative diseases, addressing the significant unmet medical need for effective treatments. The additional cell type will facilitate more targeted research into the mechanisms of neurodegeneration by using patient-derived cells. Evotec's advanced iPSC platform and panomics technology are central to this endeavor.

Evotec SE announces that Bristol Myers Squibb has exercised an exclusive global license for EVT8683, a promising drug candidate in neurodegeneration. This program has achieved FDA IND clearance and is ready for clinical development, originating from Evotec's advanced iPSC drug discovery platform. Evotec receives a $20 million option payment, with potential milestone payments of up to $250 million and low double-digit royalties. The partnership, initiated 4.5 years ago, marks a significant step towards addressing unmet medical needs in neurodegenerative diseases.

Evotec SE reported strong financial results for the first half of 2021, with revenues increasing by 17% to €271.3 million compared to €231.0 million in H1 2020. Adjusted EBITDA was €36.2 million, down from €47.3 million.

The company confirmed its full-year guidance, expecting revenues of €550-570 million and adjusted EBITDA of €105-120 million. Key developments include new partnerships, the opening of the J.POD^® 1 US facility, and plans for future capacity expansion.